These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22879832)

  • 1. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection.
    Aghemo A; Bhoori S; De Nicola S; Mazzaferro V; Colombo M
    Hepat Mon; 2012 Jun; 12(6):411-4. PubMed ID: 22879832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
    Esser-Nobis K; Romero-Brey I; Ganten TM; Gouttenoire J; Harak C; Klein R; Schemmer P; Binder M; Schnitzler P; Moradpour D; Bartenschlager R; Polyak SJ; Stremmel W; Penin F; Eisenbach C; Lohmann V
    Hepatology; 2013 Mar; 57(3):953-63. PubMed ID: 23322644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
    Wagoner J; Morishima C; Graf TN; Oberlies NH; Teissier E; Pécheur EI; Tavis JE; Polyak SJ
    PLoS One; 2011 Jan; 6(1):e16464. PubMed ID: 21297992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period.
    Bárcena R; Moreno A; Rodríguez-Gandía MA; Albillos A; Arocena C; Blesa C; García-Hoz F; Graus J; Nuño J; López-Hervás P; Gajate L; Martínez A; Bermejo T; Mateos ML; Del Campo S;
    J Hepatol; 2013 Mar; 58(3):421-6. PubMed ID: 23073223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.
    Ramadori G; Bosio P; Moriconi F; Malik IA
    BMC Cancer; 2018 Mar; 18(1):257. PubMed ID: 29510685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
    Ferenci P; Scherzer TM; Kerschner H; Rutter K; Beinhardt S; Hofer H; Schöniger-Hekele M; Holzmann H; Steindl-Munda P
    Gastroenterology; 2008 Nov; 135(5):1561-7. PubMed ID: 18771667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of fibrosing cholestatic hepatitis after liver transplantation.
    Cimsit B; Assis D; Caldwell C; Arvelakis A; Taddei T; Kulkarni S; Schilsky M; Emre S
    Transplant Proc; 2011 Apr; 43(3):905-8. PubMed ID: 21486625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
    J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue therapy with intravenous silibinin in liver transplant recipients with recurrent HCV hepatitis - two case reports.
    Socha Ł; Karpińska E; Jurczyk K; Laurans Ł; Bander D; Lachtara M; Wawrzynowicz-Syczewska M
    Ann Transplant; 2014 Apr; 19():161-4. PubMed ID: 24714452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C genotypes in liver transplant recipients: distribution and 1-year follow-up.
    Zein NN; Rakela J; Poterucha JJ; Steers JL; Wiesner RH; Persing DH
    Liver Transpl Surg; 1995 Nov; 1(6):354-7. PubMed ID: 9346611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.
    Negro F; Giostra E; Rubbia-Brandt L; Mentha G; Colucci G; Morel P; Quadri R; Perrin L; Hadengue A
    J Med Virol; 1998 Nov; 56(3):224-9. PubMed ID: 9783689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period.
    Mariño Z; Crespo G; D'Amato M; Brambilla N; Giacovelli G; Rovati L; Costa J; Navasa M; Forns X
    J Hepatol; 2013 Mar; 58(3):415-20. PubMed ID: 23063567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis viruses and liver transplantation.
    Samuel D; Feray C; Bismuth H
    J Gastroenterol Hepatol; 1997 Oct; 12(9-10):S335-41. PubMed ID: 9407355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [HCV reinfection after liver transplantation for HCV cirrhosis].
    Pasquale G; Iannicelli P; Martini S; Mogavero AR; Caprio N
    Infez Med; 2005 Dec; 13(4):215-28. PubMed ID: 16388277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation.
    Sugo H; Balderson GA; Crawford DH; Fawcett J; Lynch SV; Strong RW; Futagawa S
    Surg Today; 2003; 33(6):421-5. PubMed ID: 12768367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
    Rutter K; Scherzer TM; Beinhardt S; Kerschner H; Stättermayer AF; Hofer H; Popow-Kraupp T; Steindl-Munda P; Ferenci P
    Antivir Ther; 2011; 16(8):1327-33. PubMed ID: 22155914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
    Eurich D; Bahra M; Berg T; Boas-Knoop S; Biermer M; Neuhaus R; Neuhaus P; Neumann U
    Exp Clin Transplant; 2011 Feb; 9(1):1-6. PubMed ID: 21605016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients.
    Bizollon T; Ahmed SN; Guichard S; Chevallier P; Adham M; Ducerf C; Baulieux J; Trepo C
    Gut; 2000 Nov; 47(5):698-702. PubMed ID: 11034588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study.
    Guerrero RB; Batts KP; Burgart LJ; Barrett SL; Germer JJ; Poterucha JJ; Wiesner RH; Charlton MR; Persing DH
    Mod Pathol; 2000 Mar; 13(3):229-37. PubMed ID: 10757333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
    Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
    Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.